Gilig, Rocky Shann M.

HRN: 25-84-89  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/17/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
03/17/2025
03/23/2025
IV
105mg
Q24H
PCAP C
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: